TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00561145

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy restriction period
Description: The experiment can be divided in 3 phases, namely (1) run-in phase, (2) energy restriction phase and (3) ad libitum food intake phase. Thus, for all participants the experiment consists of three subsequent phases.
Study: NCT02335255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naftifine Hydrochloride Gel 2%
Description: Naftifine Hydrochloride Gel 2% applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naftin® Gel 2%
Description: Naftin® Gel 2% applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Topical Gel
Description: Placebo Topical Gel applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.
Study: NCT03273920

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic distal gastrectomy with D2 nodal dissection
Description: After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, robotic distal gastrectomy with D2 lymph node dissection will be performed with curative treated intent.The type of reconstruction will be determined by the surgeon's experience and preference. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic distal gastrectomy with D2 nodal dissection
Description: After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, laparoscopic distal gastrectomy with D2 lymph node dissection will be performed with curative treated intent.The type of reconstruction will be determined by the surgeon's experience and preference. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
Study: NCT01004978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Undergo TACE

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Undergo TACE

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Undergo TACE

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Undergo TACE

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin-Eluting Beads
Description: Undergo TACE

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin-Eluting Beads
Description: Undergo TACE

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin
Description: Undergo TACE

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin
Description: Undergo TACE

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study: NCT03197662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin (IN-OXT)
Description: Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril every day (4 IU each). If needed, treatment will be titrated due to side effects or non-response.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo
Description: Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril every day (4 IU each). If needed, treatment will be titrated due to side effects or non-response.
Study: NCT02752360

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biodegradable Stenting Anastomoses
Description: Biodegradable Stenting Anastomoses(BSA) is a new method and device which helps to make intestinal anastomosis easily. According to the measurement of intestinal canal diameter, chose an appropriate size of BSA and use the Seromuscular layer Purse-string Suture to stitch with an absorbable line (VCP311, Ethicon, Inc.) away from the end 0.5 to 1.0 cm and not knot temporarily, then open and sterilize intestinal canal fully, and place the BSA into the intestinal canal at appropriate position before tightening knot. Last, the interrupted whole layer inversion suture is used to fix.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Double-layer Hand Sutures
Description: Double-layer Hand Sutures(DHS)is a surgery way that is to use the single-layer continous Hand Sutures,then Lembert to stitch with an absorbable line (VCP311, Ethicon, Inc.).
Study: NCT01575756

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Octafibrin
Description: Octafibrin was supplied as a powder for reconstitution with water for injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Octafibrin
Description: Octafibrin was supplied as a powder for reconstitution with water for injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haemocomplettan® P or RiaSTAPTM
Description: Commercially available Haemocomplettan® P or RiaSTAPTM (same product with different names in different markets) were supplied as powders for reconstitution with water for injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haemocomplettan® P or RiaSTAPTM
Description: Commercially available Haemocomplettan® P or RiaSTAPTM (same product with different names in different markets) were supplied as powders for reconstitution with water for injection.
Study: NCT00508911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW876008
Description: GW876008 tablets will be available as white to off-white coated tablets. Each subject will receive a single oral dose of GW876008, daily for up to 35 days in Session 2. GW876008 will be administered in the morning with a light breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COC
Description: COC containing ethinylestradiol 30 microgram and levonorgestrel 150 microgram will be administered in the morning with a light breakfast.
Study: NCT00527280

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Feasibility ot face transplantation
Description: Feasibility ot face transplantation
Study: NCT01438112

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CG0070 Adenovirus Vector
Description: CG0070 adenoviral vector with GM-CSF expression given intravesically 1x10e12 viral particles for each instillations, weekly times six

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Arm: Quadruple Choice
Description: Quadruple Choice Treatment Options: (same as listed above)
Study: NCT04024605

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sunflower
Description: Plant proteins are intrinsically enriched with 15N and 2H. There are incorporated into biscuits. The biscuits are formulated to supply 20 g of plant protein per volunteer.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rapeseed
Description: Plant proteins are intrinsically enriched with 15N and 2H. There are incorporated into biscuits. The biscuits are formulated to supply 20 g of plant protein per volunteer.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed
Description: Plant proteins are intrinsically enriched with 15N and 2H. There are incorporated into biscuits. The biscuits are formulated to supply 20 g of plant protein per volunteer.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lupin
Description: Plant proteins are intrinsically enriched with 15N and 2H. There are incorporated into biscuits. The biscuits are formulated to supply 20 g of plant protein per volunteer.
Study: NCT02534597

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotores Training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotores Training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed Promotores training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed Promotores training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed Promotores training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed Promotores training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed Promotores training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed Promotores training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed Promotores training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed Promotores training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed caregiver training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed caregiver training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed caregiver training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Materials support

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Materials support

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed materials support

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed materials support

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technical assistance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technical assistance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technical assistance
Study: NCT00594880

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Interferon-alpha 2a, 180 mcg/week sc
Description: Pegylated Interferon-alpha 2a, 90 mcg/week sc for 24 weeks, 5 weeks in combination with ART, then 7 weeks without ART to primary endpoint (VL \< 400 c/ml at 12 weeks) and further 12 weeks without ART (24 weeks) to secondary endpoints
Study: NCT02534597

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technical assistance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed technical assistance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed technical assistance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed technical assistance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed technical assistance
Study: NCT01749410

Intervention type: BIOLOGICAL
Intervention: onabotulinumtoxinA
Description: Previous treatment with onabotulinumtoxinA for Chronic Migraine.
Study: NCT04194983

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oils and dairy fat
Description: 12-weeks, 3x per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fish oils and plant fat
Description: 12-weeks, 3x per day
Study: NCT03703752

Intervention type: DIAGNOSTIC_TEST
Intervention: Multi-detector CT scan
Description: This is a diagnostic radiological test to diagnose the IH and evaluate the clinical condition of IH

Intervention type: DIAGNOSTIC_TEST
Intervention: Multi-detector CT scan
Description: This is a diagnostic radiological test to diagnose the IH and evaluate the clinical condition of IH
Study: NCT00594880

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Interferon-alpha 2a, 90 mcg/week sc
Description: Pegylated Interferon-alpha 2a, 90 mcg/week sc for 24 weeks, 5 weeks in combination with ART, then 7 weeks without ART to primary endpoint (VL \< 400 c/ml at 12 weeks) and further 12 weeks without ART (24 weeks) to secondary endpoints
Study: NCT02217215

Intervention type: DEVICE
Intervention: CNDS Advanced Cervical Scan
Description: Subjects (approximately 500) will be initially enrolled from a general screening population in the first phase, and during the second phase from the colposcopy clinic population (approximately 300) based on their referral abnormal Pap cytology conducted within 120-days in order to achieve a statistically viable number of normal women, women with CIN1/2 and women with CIN3+, as described in Section 6.1, Cervical Cytology Enrollment Targets. After the CNDS test, a sample for Hybrid Capture 2 HPV testing and liquid cytology will be collected in addition to colposcopy and biopsy, if indicated.
Study: NCT03557671

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: rice formula
Description: new rice based thickened formula

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: rice formula
Description: new rice based thickened formula

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: formula previously tolerated by the subject - only for the 1st part of the study

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: placebo
Description: formula previously tolerated by the subject - only for the 1st part of the study
Study: NCT02936882

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Preoperative gastric ultrasonography
Description: Before surgical emergency procedure, a preoperative antral ultrasonography is performed to assess gastric content.
Study: NCT01344551

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa Drink
Description: High Flavanol (495mg) Low Flavanol (23mg) Matched for macro and micro nutrients

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cocoa Drink
Description: High Flavanol (495mg) Low Flavanol (23mg) Matched for macro and micro nutrients
Study: NCT01254747

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A contact lens
Description: Investigational silicone hydrogel, single vision contact lens for daily wear, daily disposable use

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lotrafilcon B contact lens (O2 OPTIX, AIR OPTIX)
Description: Commercially marketed silicone hydrogel, single vision contact lens for daily wear, daily disposable use

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nelfilcon A contact lens (DAILIES AquaComfort Plus)
Description: Commercially marketed hydrogel, single vision contact lens for daily wear, daily disposable use

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Narafilcon A contact lens (1-DAY ACUVUE TRUEYE)
Description: Commercially marketed (Europe) silicone hydrogel, single vision contact lens for daily wear, daily disposable use
Study: NCT02406677

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study voucher card
Description: Study voucher card to offset any patient copayments or medication costs for the filling of any prescriptions of clopidogrel or ticagrelor
Study: NCT01114880

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Prefilled syringe, 40 mg/0.8 mL administered subcutaneously every other week

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: adalimumab
Description: Prefilled syringe, 40 mg/0.8 mL administered subcutaneously every other week

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Prefilled syringe, matching placebo administered subcutaneously every other week
Study: NCT02817906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-007

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01173432

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous positive airway pressure
Description: an device to be used during sleep, which was a nasal mask connected to a device with pressure applied to upper airway
Study: NCT01708343

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DIMMST

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DIMMST

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: DIMMST
Study: NCT02273258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR342434
Description: Pharmaceutical form:solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Pharmaceutical form:solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study: NCT02625064

Intervention type: OTHER
Intervention: Blood samples collection before treatment

Intervention type: OTHER
Intervention: Blood samples collection before treatment

Intervention type: OTHER
Intervention: Blood samples collection before treatment

Intervention type: OTHER
Intervention: Blood samples collection before treatment

Intervention type: OTHER
Intervention: Blood samples collection before treatment

Intervention type: OTHER
Intervention: Blood samples collection after treatment

Intervention type: OTHER
Intervention: Blood samples collection after treatment

Intervention type: OTHER
Intervention: Blood samples collection after treatment

Intervention type: OTHER
Intervention: Blood samples collection after treatment

Intervention type: OTHER
Intervention: Blood samples collection after treatment

Intervention type: OTHER
Intervention: laboratory biomarker proteomic analysis

Intervention type: OTHER
Intervention: laboratory biomarker proteomic analysis

Intervention type: OTHER
Intervention: laboratory biomarker proteomic analysis

Intervention type: OTHER
Intervention: laboratory biomarker proteomic analysis

Intervention type: OTHER
Intervention: laboratory biomarker proteomic analysis
Study: NCT01690377

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDC or myDC
Description: PDC or myDC; first patient 0.3 \* 10E6 PDC; second and third 1 \* 10E6 PDC; fourth and fifth 3 \* 10E6 PDC.
Study: NCT04033302

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD7-specific CAR gene-engineered T cells
Description: Infusion of CD7-specific CAR-T cells
Study: NCT03859063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Participants randomized to the intervention arm will be followed with monthly meetings by a stroke coordinator for 18 months. The stroke coordinator will assess the patients risk factors within the domains of physical function, cognitive function, social function, medication and lifestyle factors and make a treatment plan targeting the individual needs for further follow-up.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Community based follow-up as usual
Study: NCT02145468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losmapimod 7.5 mg twice daily
Description: Subjects will receive Losmapimod 7.5 mg as film-coated, round, plain faced tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo twice daily
Description: Subjects will receive placebo as film-coated, round, plain faced tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy
Description: Subjects will receive standard therapy consistent with the appropriate guidelines from professional societies. The standard therapy includes nitrates, morphine sulfate, beta adrenergic blockers, renin-angiotensin aldosterone inhibitors, other anti-ischemic therapies, and analgesic therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard therapy
Description: Subjects will receive standard therapy consistent with the appropriate guidelines from professional societies. The standard therapy includes nitrates, morphine sulfate, beta adrenergic blockers, renin-angiotensin aldosterone inhibitors, other anti-ischemic therapies, and analgesic therapy.
Study: NCT03023553

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fluzone®
Description: Influenza Virus Vaccine Suspension for Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: FluMist®
Description: Influenza Virus Vaccine Live, Intranasal Spray
Study: NCT02408991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neupogen
Description: Neupogen is given as an injection in your skin every three days for a total of 5 doses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Art-Assist Device
Description: The programmed pneumatic compression device (PPCD) is to be worn for a minimum of three hours daily while patient is sitting down
Study: NCT02372344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0585
Description: Following an overnight fast of at least 10 hours, a single dose of 4 g AZD0585 will be administered on 3 separate occasions (fasting, before meal, and after meal) in a randomized crossover fashion with different food restrictions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0585
Description: Following an overnight fast of at least 10 hours, a single dose of 4 g AZD0585 will be administered on 3 separate occasions (fasting, before meal, and after meal) in a randomized crossover fashion with different food restrictions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0585
Description: Following an overnight fast of at least 10 hours, a single dose of 4 g AZD0585 will be administered on 3 separate occasions (fasting, before meal, and after meal) in a randomized crossover fashion with different food restrictions.